A comparison of in vitro methods for assessing the potency of therapeutic antisera against the venom of the coral snake Micrurus nigrocinctus.
Therapeutic antisera against Micrurus nigrocinctus venom were tested for protection against lethality, as well as for inhibition of the nicotinic acetylcholine receptor (AchR)-binding and neutralization of phospholipase A2 (PLA2) activities of the homologous venom. Protection against venom lethality did not correlate with inhibition of AchR-binding activity, whereas there was a significant correlation between antisera potency and inhibition of PLA2 activity (r = 0.82, n = 10, P < 0.02). Inhibition of PLA2 activity could be useful in assessing the protective efficacy of M. nigrocinctus antisera during antivenom production. Micrurus nigrocinctus nigrocinctus venom proteins were fractionated by cation-exchange chromatography on Mono S FPLC and fractions assayed for lethality, AchR-binding and PLA2 activities. Antisera were titrated by enzyme-linked immunoassay (ELISA) against a crude M. n. nigrocinctus venom, two FPLC lethal fractions containing AchR-binding activity, and two toxins purified from M. n. nigrocinctus venom. No correlation was found between protective efficacy and the ELISA titer against any of these antigens. Compared to other elapid venoms that contain few toxins as major components, M. n. nigrocinctus venom appears to be more complex and its lethal effect is likely to be due to the combined effect of several neurotoxins.
Alape-Girón
A
A
Instituto Clodomiro Picado, Facultad de Microbiologia, San José, Costa Rica.
Miranda-Arrieta
K
K
Cortes-Bratti
X
X
Stiles
B G
BG
Gutiérrez
J M
JM
D000818:Animals; D000997:Antivenins / Q000276:immunology* / Q000627:therapeutic use*; D004546:Elapid Venoms / Q000737:chemistry / Q000276:immunology* / Q000633:toxicity*; D017815:Elapidae; D004797:Enzyme-Linked Immunosorbent Assay; D051379:Mice; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D011978:Receptors, Nicotinic / Q000378:metabolism*; D012909:Snake Bites / Q000628:therapy
D000997:Antivenins; D004546:Elapid Venoms; D011978:Receptors, Nicotinic; D010741:Phospholipases A; D054467:Phospholipases A2